CN110191704A - 可分散组合物 - Google Patents

可分散组合物 Download PDF

Info

Publication number
CN110191704A
CN110191704A CN201780065671.8A CN201780065671A CN110191704A CN 110191704 A CN110191704 A CN 110191704A CN 201780065671 A CN201780065671 A CN 201780065671A CN 110191704 A CN110191704 A CN 110191704A
Authority
CN
China
Prior art keywords
composition
peg
tablet
pharmaceutically acceptable
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780065671.8A
Other languages
English (en)
Chinese (zh)
Inventor
H.帕坦卡尔
N.M.F.戈伊瓦尔茨
G.R.朗加拉赞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Janssen R&D Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R&D Ireland ULC filed Critical Janssen R&D Ireland ULC
Publication of CN110191704A publication Critical patent/CN110191704A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780065671.8A 2016-10-24 2017-10-23 可分散组合物 Pending CN110191704A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621036404 2016-10-24
IN201621036404 2016-10-24
PCT/EP2017/077030 WO2018077815A1 (en) 2016-10-24 2017-10-23 Dispersible compositions

Publications (1)

Publication Number Publication Date
CN110191704A true CN110191704A (zh) 2019-08-30

Family

ID=60262899

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780065671.8A Pending CN110191704A (zh) 2016-10-24 2017-10-23 可分散组合物

Country Status (21)

Country Link
US (2) US11065198B2 (cg-RX-API-DMAC7.html)
EP (2) EP3528791B1 (cg-RX-API-DMAC7.html)
JP (2) JP7197474B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190073450A (cg-RX-API-DMAC7.html)
CN (1) CN110191704A (cg-RX-API-DMAC7.html)
CA (1) CA3039562A1 (cg-RX-API-DMAC7.html)
DK (1) DK3528791T3 (cg-RX-API-DMAC7.html)
ES (1) ES2970870T3 (cg-RX-API-DMAC7.html)
FI (1) FI3528791T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240118T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064823T2 (cg-RX-API-DMAC7.html)
LT (1) LT3528791T (cg-RX-API-DMAC7.html)
MA (1) MA46563B1 (cg-RX-API-DMAC7.html)
MX (1) MX2019004767A (cg-RX-API-DMAC7.html)
PL (1) PL3528791T3 (cg-RX-API-DMAC7.html)
PT (1) PT3528791T (cg-RX-API-DMAC7.html)
RS (1) RS65159B1 (cg-RX-API-DMAC7.html)
SI (1) SI3528791T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400060T1 (cg-RX-API-DMAC7.html)
TW (1) TWI821163B (cg-RX-API-DMAC7.html)
WO (1) WO2018077815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
GB202211231D0 (en) * 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
WO2015120014A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
WO2015176008A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (en) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Compression-coated dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056673A (zh) * 2004-09-02 2007-10-17 詹森药业有限公司 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐
WO2015120014A1 (en) * 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
WO2015136294A1 (en) * 2014-03-13 2015-09-17 Cipla Limited Pharmaceutical composittion comprising rilpivirine
WO2015176008A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张媛主编: "《中药制剂技术》", 31 August 2012, 河南科学技术出版社 *
谢秀琼主编: "《现代中药制剂新技术》", 30 June 2004, 化学工业出版社 *

Also Published As

Publication number Publication date
TWI821163B (zh) 2023-11-11
US20220008333A1 (en) 2022-01-13
MA46563A (fr) 2019-08-28
RU2019115672A (ru) 2020-11-24
RS65159B1 (sr) 2024-02-29
SI3528791T1 (sl) 2024-04-30
TW201828927A (zh) 2018-08-16
KR102861006B1 (ko) 2025-09-16
US11065198B2 (en) 2021-07-20
EP3528791B1 (en) 2023-12-06
ES2970870T3 (es) 2024-05-31
JP2020500168A (ja) 2020-01-09
JP7197474B2 (ja) 2022-12-27
SMT202400060T1 (it) 2024-03-13
PT3528791T (pt) 2024-02-19
EP4248947A2 (en) 2023-09-27
JP2023011659A (ja) 2023-01-24
MA46563B1 (fr) 2024-01-31
MX2019004767A (es) 2019-07-01
EP4248947A3 (en) 2023-11-22
CA3039562A1 (en) 2018-05-03
HRP20240118T1 (hr) 2024-04-12
KR20190073450A (ko) 2019-06-26
US20200069579A1 (en) 2020-03-05
LT3528791T (lt) 2024-05-27
BR112019007564A2 (pt) 2019-07-02
PL3528791T3 (pl) 2024-04-02
EP3528791A1 (en) 2019-08-28
WO2018077815A1 (en) 2018-05-03
HUE064823T2 (hu) 2024-04-28
RU2019115672A3 (cg-RX-API-DMAC7.html) 2021-01-21
DK3528791T3 (da) 2024-01-29
KR20240011873A (ko) 2024-01-26
FI3528791T3 (fi) 2024-01-30

Similar Documents

Publication Publication Date Title
AU2021204135B2 (en) Dispersible compositions
JP2023011659A (ja) 分散性組成物
HK40101645A (en) Dispersible compositions
RU2826218C2 (ru) Диспергируемые композиции
HK40013979B (en) Dispersible compositions
HK40013979A (en) Dispersible compositions
HK40013937A (en) Dispersible compositions
CN101068597B (zh) 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
HK40069676A (en) Dispersible compositions
BR112019007564B1 (pt) Composições dispersíveis, seu processo de fabricação e uso de rilpivirina
CA2973301C (en) Dispersible compositions comprising bedaquiline fumarate
EA042247B1 (ru) Диспергируемые композиции
OA18325A (en) Dispersible compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013937

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190830